Date: 2017-01-09
Type of information: Nomination
Compound: chief executive officer
Company: Leon-nanodrugs (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 9, 2017, leon nanodrugs appoints pharma expert Michael Mehler, Sc.D. as new chief executive officer of the Munich based company and its U.S. subsidiary leon-nanodrugs Inc. He succeeds Dr. Theron (Ted) Odlaug who will continue to serve the company in the Supervisory Board, as was agreed at the beginning of 2016.
- Dr. Michael Mehler brings to leon-nanodrugs over 25 years of experience holding significant leadership roles in the international pharma and biotechnology industries. In his previous tenure he was the CEO of SpePharm, a pan-European specialty pharma company focused on high-value specialty hospital products. Prior to that he led Riemser Arzneimittel , now Riemser Pharma, as CEO from 2009 to 2014 and guided the company through the sale to AXA Private Equity, in 2012. From 2003 to 2009 he served Actelion Pharmaceuticals in several senior executive roles, Michael started his long-time international career at Merck/MSD and Novartis. Michael graduated in Chemical Engineering from the Technical University in Darmstadt and holds a Doctor’s degree (Dr. rer. nat; Sc.D.) in Biochemistry from the University of Mainz.
Financial terms:
Latest news:
Is general: Yes
